PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Kathy D. Miller, M.D.
Hoosier Cancer Research Network
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- St. Jude Heritage Healthcare
Fullerton, California, United States
- University of California Los Angeles
Los Angeles, California, United States
- Central Coast Medical Oncology Corporation
Santa Maria, California, United States
- University of Colorado Cancer Center
Aurora, Colorado, United States
- Memorial Cancer Institute Breast Cancer Center
Hollywood, Florida, United States
- University of Miami, Sylvester Comprehensive Cancer Center
Miami, Florida, United States
- Fort Wayne Oncology & Hematology, Inc
Fort Wayne, Indiana, United States
- Community Regional Cancer Center
Indianapolis, Indiana, United States
- Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
- Horizon Oncology Research, Inc./iu Health Arnett
Lafayette, Indiana, United States
- Monroe Medical Associates
Munster, Indiana, United States
- Northern Indiana Cancer Research Consortium
South Bend, Indiana, United States
- Metro Health Cancer Care
Wyoming, Michigan, United States
- Siteman Cancer Center
St Louis, Missouri, United States
- Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
- the Center for Cancer & Hematologic Disease
Cherry Hill, New Jersey, United States
- Virtua Health Cancer Program
Mount Holly, New Jersey, United States
- South Jersey Health Care
Vineland, New Jersey, United States
- Presbyterian Medical Group
Albuquerque, New Mexico, United States
- University of New Mexico Cancer Center: Albuquerque
Albuquerque, New Mexico, United States
- Hope A Women'S Cancer Center
Asheville, North Carolina, United States
- Seidman Cancer Center
Cleveland, Ohio, United States
- Oregon Health Sciences University
Portland, Oregon, United States
- Pinnacle Health Fox Chase Regional Cancer Center
Harrisburg, Pennsylvania, United States
- Bux-Mont Oncology Hematology Associates (fccc) at Grand View Hospital
Sellersville, Pennsylvania, United States
- the West Clinic
Memphis, Tennessee, United States
- Virginia Oncology Associates
Norfolk, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2010
- Primary completion
- 15 Dec 2018
- Completion
- 15 Dec 2018
- Last update posted
- 19 Sept 2024
- Registered enrollment
- 135
- Registry id
- NCT01074970
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.